Safety and feasibility of 2 h of normothermic machine perfusion of donor kidneys in the Eurotransplant Senior Program

E. Rijke 
1, J. de Jonge1, H. J. A. N. Kimenai2, M. J. Hoogduijn2, R. W. F. de Bruin1, M. W. F. van den Hoogen2, J. N. M. IJzermans1 and R. C. Minnee1, *}

1 Division of Hepato-Pancreato-Biliary and Transplant Surgery, Department of Surgery, Erasmus MC University Medical Centre, Rotterdam, the Netherlands
2 Nephrology and Transplantation, Department of Internal Medicine, Erasmus MC University Medical Centre, Rotterdam, the Netherlands
*Correspondence to: Division of Hepato-Pancreato-Biliary and Transplant Surgery, Department of Surgery, Erasmus MC University Medical Centre, Doctor Molewaterplein 40, 3015 GD Rotterdam, the Netherlands (e-mail: r.minnee@erasmusmc.nl)

Presented to the European Society for Organ Transplantation Congress in Copenhagen, Denmark (September 2019) and the Dutch Transplant Conference in Roermond, the Netherlands (March 2020)

Abstract

Background: The 5-year graft survival rate of donor kidneys transplanted in the Eurotransplant Senior Program (ESP) is only 47 per cent. Normothermic machine perfusion (NMP) may be a new preservation technique that improves graft outcome. This pilot study aimed to assess safety and feasibility of this technique within the ESP.

Methods: Recipients were eligible for inclusion if they received a donor kidney within the ESP. Donor kidneys underwent 2 h of oxygenated NMP with a red cell-based solution at 37°C, additional to standard-of-care preservation (non-oxygenated hypothermic machine perfusion). The primary outcome was the safety and feasibility of NMP. As a secondary outcome, graft outcome was investigated and compared with that in a historical group of patients in the ESP and the contralateral kidneys.

Results: Eleven patients were included in the NMP group; the function of eight kidneys could be compared with that of the contralateral kidney. Fifty-three patients in the ESP, transplanted consecutively between 2016 and 2018, were included as controls. No adverse events were noted, especially no arterial thrombosis or primary non-function of the transplants. After 120 min of oxygenated NMP, median flow increased from 117 (I.q.r. 80–126) to 215 (170–276) ml/min (P = 0.001). The incidence of immediate function was 64 per cent in the NMP group and 40 per cent in historical controls (P = 0.144). A significant difference in graft outcome was not observed.

Discussion: This pilot study showed NMP to be safe and feasible in kidneys transplanted in the ESP. A well powered study is warranted to confirm these results and investigate the potential advantages of NMP on graft outcome.

Introduction

Kidney transplantation is the only life-saving treatment for end-stage renal disease. Because the demand for suitable donor kidneys exceeds the supply, death while being waitlisted for a donor kidney to become available is a major problem. One solution to increase the donor pool is the more frequent use of expanded criteria donor (ECD) and donation after circulatory death (DCD) kidneys. Unfortunately, ECD kidneys are known to have a 70 per cent increased risk of graft failure, resulting in earlier return to dialysis or retransplantation. One example of the use of these ECD and DCD kidneys is the Eurotransplant Senior Program (ESP), in which kidneys from donors aged 65 years or more are allocated to recipients aged 65 years or above, focusing on short ischemia time to minimize additional organ damage. Unfortunately, ESP results have shown high rates of delayed graft function (DGF) and primary non-function (PNF), with a 5-year graft survival rate of only 47 per cent. Especially for DCD kidneys transplanted within the ESP, the reported incidence of DGF and PNF is 74.1 and 12.4 per cent respectively. Therefore, attempts to improve outcomes in this particular group of recipients are important.

In the past decade, machine perfusion has regained interest as a promising preservation technique for deceased donor organs. Moers and colleagues showed that preservation with hypothermic machine perfusion (HMP) improved clinical outcomes after kidney transplantation in comparison with static cold storage (SCS). Unfortunately, in this RCT, patients transplanted in the ESP had minimal benefit from HMP. Additional preservation methods may be needed in these suboptimal donor kidneys, such as normothermic machine perfusion (NMP). NMP has several advantages in addition to HMP alone. First, NMP allows for pretransplantation viability assessment as the kidney becomes metabolically active. Donor kidney function can be assessed before transplantation, which has been shown to reduce discard rates.
Second, in contrast to HMP, NMP can improve kidney function through active repair and reconditioning. NMP itself may improve kidney function as previous clinical studies showed a decreased incidence of DGF compared with that in donor kidneys not receiving NMP\textsuperscript{10,11}. In addition, NMP can provide a platform for kidney-tailored organ repair by adding therapies ‘on the pump’, such as mesenchymal stem cells\textsuperscript{12,13}. This may be of special interest in suboptimal donor kidneys, such as those transplanted within the ESP population. Third, NMP could extend preservation time without prolonging ischaemia time. This could be beneficial for several reasons, such as more time to find an appropriate match and preparation of the operative procedure. When there are several kidney offers at the same time, NMP can delay transplantation safely without compromising the quality of the graft because of prolonged cold ischaemia time.

Although NMP is theoretically attractive, its application in deceased donor kidney transplantation is largely unknown, as only a few centres have published on this technique in a clinical kidney transplantation setting\textsuperscript{10,11,14,15}. NMP is more complex, expensive, and sensitive to technical problems such as inhomogeneous perfusion, perfusate toxicity, and perfusion-related organ damage. Moreover, in contrast to HMP, failure of NMP leads to detrimental extra warm ischaemia time. Therefore, the aim of this study was to investigate the safety and feasibility of implementing 2 h of NMP in the ESP.

Methods

This prospective, single-centre pilot study aimed to include 10 ESP recipients of a technically successful NMP procedure. Between 1 January 2018 and 1 December 2018, all waitlisted patients aged 65 years or above were asked to participate. Patients were excluded if they received a dual kidney transplant. Multiple renal arteries in the donor organ were not a contraindication for inclusion as arterial reconstruction could be performed safely before the NMP procedure. All kidneys were allocated according to the regular Eurotransplant rules based on blood-type compatibility and waiting time. All donor kidneys included in the study were suitable for transplantation based on standard criteria before the start of NMP. Both donation after brain death (DBD) and DCD kidneys were included. The study was performed in Erasmus Medical Centre, Rotterdam, the Netherlands, and approved by the local medical ethics committee (POSEIDON study, MEC 2017-503). All recipients provided informed consent to participate in the study.

Kidney procurement

The donor procedure was carried out in the donor hospital, according to the standard Eurotransplant retrieval procedure. For DCD donors, a 5-min period of ‘no touch’ after asystole was maintained, according to Dutch law. Thereafter, the donor was transported immediately to the operating room. The super-rapid recovery technique was used to perform aortic flush with at least 5 litres of ice-cold (0–4°C) Belzer University of Wisconsin (UW\textsuperscript{9}) Cold Storage Solution (Bridge to Life, London, UK) to which 25 000 U heparin was added. After procurement, the donor kidney was stored on SCS.

Normothermic machine perfusion and transplantation procedure

Upon arrival of the donor kidney at Erasmus Medical Centre, the kidney was disconnected from the HMP device under sterile conditions. Thereafter, acceptability for transplantation was assessed. The Kidney Assist (Organ Assist, Groningen, the Netherlands) used for NMP provides pressure-controlled perfusion with a rotary pump. Perfusion was performed with an oxygenated, plasma-free, red cell-based solution, based largely on the perfusate, as described by Hosgood et al.\textsuperscript{14} The composition of the perfusate is detailed in Table 1. After preparation of the Kidney Assist, the renal artery was cannulated with a sterile 3-mm PVC funnel (Teleflex, Athlone, Ireland). The kidney was then connected to the Kidney Assist.

Oxygenated NMP was started at 37°C with 100 per cent oxygen at a pressure of 60 mmHg, which was increased manually if deemed necessary based on the colour of the kidney. Urine produced during NMP was recirculated to keep the volume constant, as has been shown to maintain a more physiological perfusate composition and improved flow during NMP\textsuperscript{16}. Perfusion parameters during NMP such as flow, intrarenal resistance, and pressure were registered continuously. After 2 h of NMP, the donor kidney was stored on SCS as briefly as possible until the operating team was ready to perform the kidney transplantation. Upon transplantation, the donor kidney was routinely implanted in the iliac fossa and connected to the external iliac artery and vein. The anastomosis between donor ureter and recipient bladder was an extravesical anastomosis with the use of an external splint. Immunosuppression of the recipients consisted of triple therapy with prednisolone, tacrolimus, mycophenolate mofetil and basiliximab as induction therapy. In the case of multiple arteries and renal artery reconstruction, patients received 12 000 units heparin per 24 h for 5 days, as standard of care in the kidney transplant programme.

Primary and secondary outcomes

The primary outcome of the study was the safety and feasibility of NMP. Any adverse events in the postoperative period or problems during NMP were recorded. Special attention was given to technical issues such as machine failure and inability to perform NMP or decannulation. Unfavourable short-term transplant outcomes, such as FNF, early rejection, graft infection and graft thrombosis, were also noted. Logistical issues were noted, paying particular attention to the duration of cold ischaemia time.

Table 1 Composition of perfusate used for normothermic machine perfusion

| Content | Final concentration |
|---------|---------------------|
| Compatible cross-matched blood (ml) | 250 |
| Sterofundin\textsuperscript{©} solution (ml) | 500–1000 |
| Mannitol 15% (ml) | 10–20 |
| Dexamethasone 4 mg (ml) | 2 |
| Sodium bicarbonate 8.4% (ml) | 10–40 |
| Heparin 1000 units/ml (ml) | 2–4 |
| Augmentin 1.2 g (ml) | 10 |
| Prostacyclin 0.5 mg (ml/h) | 4 |
| Glucose 5% (ml/h) | 7 |
| Nutriflex\textsuperscript{®} infusion\textsuperscript{®} with the following added | 20 |
| Insulin (units) | 100 |
| Sodium bicarbonate 8.4% (ml) | 25 |
| Multivitamins (ml) | 5 |

*B. Braun, Melsungen, Germany.
NMP procedure should not prolong cold ischaemia time, as this impacts graft outcome.

Secondary outcomes were graft outcomes, defined as the incidence of immediate kidney function (no DGF/PNF), biopsy-proven acute rejection (BPAR) within 3 months, post-transplantation estimated glomerular filtration rate (eGFR), and graft and patient survival. eGFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula. For graft survival, both death-censored and uncensored graft survival were investigated. DGF was defined as the need for dialysis treatment in the first week after transplantation. PNF was defined as a never functioning graft and was diagnosed retrospectively 3 months after transplantation. Graft outcome was investigated and compared with that in two control groups. The first control group was a historical cohort of consecutive patients in the ESP transplanted without the use of NMP between 1 January 2016 and 31 December 2018. In this control group, cold preservation of the kidney was usually performed with HMP, and for incidental cases with SCS. To reduce bias by confounding, a second control group was formed consisting of the contralateral kidney of each included donor kidney, if that kidney was also transplanted.

**Statistical analysis**

For baseline characteristics, continuous variables were presented as median (i.q.r.) values, and comparisons were done using the Mann–Whitney U test. Categorical variables were presented as numbers and percentages, and compared with the χ² or Fisher’s exact test, based on expected and observed counts. For comparisons made with the contralateral kidney and for correlated measurements, the Wilcoxon signed rank test was used for continuous data and the McNemar test for categorical data. For the outcome eGFR, if graft failure had taken place, an eGFR of 10 ml/min was imputed. If a patient died with a functioning graft, the last observation of eGFR was carried forward. Survival analysis was performed using the Kaplan-Meier method and curves were compared with the log-rank test. Two-sided P < 0.050 was considered statistically significant. All analyses were performed using GraphPad Prism® version 5.0 (GraphPad, San Diego, CA, USA) and IBM SPSS® Statistics version 25 (IBM, Armonk, NY, USA).

**Results**

Between 1 March 2018 and 1 December 2018, 11 deceased donor kidneys transplanted into recipients participating in the ESP received 2 h of NMP. One protocol violation took place, as one of the donors was aged 63 years and 10 months; this became apparent only once the NMP procedure had started.

**Table 2 Baseline characteristics of patients receiving a normothermic machine perfused kidney and historical controls**

|                           | NMP group (n=11) | Historical control group (n=53) | P*  |
|---------------------------|------------------|--------------------------------|-----|
| **Recipient characteristics** |                  |                                |     |
| Age (years)*              | 71 (67–74)       | 70 (69–75)                     | 0.580<sup>4</sup> |
| Male sex                  | 9 (82)           | 28 (53)                        | 0.076 |
| BMI (mg/kg<sup>2</sup>)*  | 26.7 (24.7–31.0) | 27.4 (24.9–30.8)               | 0.873<sup>4</sup> |
| Diabetes                  | 2 (18)           | 22 (42)                        | 0.146 |
| Dialysis treatment        |                  |                                | 0.280 |
| None                      | 3 (27)           | 6 (11)                         |     |
| Haemodialysis             | 5 (45)           | 36 (68)                        |     |
| Peritoneal dialysis       | 3 (27)           | 11 (21)                        |     |
| Time on dialysis (months)*| 22.5 (14.3–45.3) | 22.1 (14.4–32.5)               | 0.699<sup>4</sup> |
| HLA mismatch              | 4 (3–5)          | 5 (4–5)                        | 0.229<sup>4</sup> |
| Current PRA†              | 0 (0–4)          | 0 (0–0)                        | 0.207<sup>4</sup> |
| Smoking                   |                  |                                | 0.772 |
| Never                     | 4 (36)           | 24 (45)                        |     |
| Current                   | 2 (18)           | 6 (11)                         |     |
| Previous                  | 5 (45)           | 23 (43)                        |     |
| Ischaemic heart disease   | 2 (18)           | 12 (23)                        | 0.745 |
| **Donor characteristics** |                  |                                |     |
| DBD donor                 | 4 (36)           | 13 (25)                        | 0.419 |
| Age (years)*              | 71 (66–72)       | 69 (68–73)                     | 0.872<sup>4</sup> |
| Male sex                  | 7 (64)           | 27 (51)                        | 0.443 |
| BMI (kg/m<sup>2</sup>)*   | 22.2 (18.1–26.1) | 25.6 (23.6–28.2)               | 0.043<sup>4</sup> |
| First WIT (min)*          | 13 (0–17)        | 13 (2–15)                      | 0.921<sup>4</sup> |
| **Transplant characteristics** |                |                                |     |
| Second CIT (min)*         | 83 (34–167)      | –                              | 0.893<sup>4</sup> |
| Total CIT (min)           | 593 (497–746)    | 600 (480–720)                  |     |
| Second WIT (min)*         | 18.0 (17.0–21.0) | 22.0 (17.5–28.5)               | 0.095<sup>4</sup> |
| Arterial reconstruction   | 5 (45)           | 13 (25)                        | 0.160 |
| Cold preservation method  | HMP              | 44 (83)                        | 0.426 |
| Static cold storage       | 3 (27)           | 9 (17)                         |     |

Values in parentheses are percentages unless indicated otherwise: *values are median (i.q.r.). NMP, normothermic machine perfusion; HLA, human leucocyte antigen; PRA, panel-reactive antibodies; DBD, donation after brain death; WIT, warm ischaemia time; CIT, cold ischaemia time; HMP, hypothermic machine perfusion. †χ² or Fisher’s exact test, except Mann–Whitney U test.
between perfusion parameters at the start and end of NMP.

Table 3

|                          | Start of NMP | End of NMP | P* |
|--------------------------|--------------|------------|----|
| Flow (ml/min)            | 117 (80–126) | 215 (170–276) | 0.001 |
| Perfusate pH             | 7.52 (7.05–7.58) | 7.62 (7.53–7.84) | 0.037 |
| Perfusate lactate (mmol/l)| 5.1 (4.5–5.6) | 11.9 (10.3–13.4) | 0.001 |
| Perfusate glucose (mmol/l)| 10.6 (5.9–13.0) | 10.9 (5.8–12.8) | 0.182 |
| Perfusate potassium (mmol/l)| 7.6 (7.2–9.7) | 8.8 (7.0–9.9) | 0.906 |
| Perfusate sodium (mmol/l)| 145 (143–147) | 149 (146–153) | 0.005 |
| Perfusate calcium (mmol/l)| 1.25 (1.16–1.29) | 1.21 (1.15–1.28) | 0.682 |

Values are median (i.q.r.). NMP, normothermic machine perfusion. * Wilcoxon signed rank test.

Median flow was 117 (i.q.r. 80–126) ml/min at the start of NMP, increasing significantly to 215 (170–276) ml/min at the end (P = 0.001). Median perfusate pH, lactate and sodium increased significantly, whereas glucose, potassium and calcium perfusate remained constant.

**Secondary outcome: graft outcome**

**Normothermic machine perfusion versus Eurotransplant Senior Program cohort**

To select a larger reference control group, 53 consecutive patients in the ESP were selected, who had been transplanted between 1 January 2016 and 31 December 2018. Table 2 presents baseline characteristics for this control group in comparison with the NMP group. Donor BMI was significantly lower in the NMP group than in the historical controls (median 22.2 (i.q.r. 18.1–26.1) versus 25.6 (23.6–28.2) kg/m² respectively; P = 0.043). Other baseline characteristics were not significantly different. Despite an additional second cold ischaemia time in the NMP group, total cold ischaemia time was similar in the two groups (P = 0.893).

Results of graft outcome in the NMP and ESP control groups are summarized in Table 4. Seven of the 11 patients (64 per cent) in the NMP group had immediate kidney function, compared with 21 of the 53 patients (40 per cent) in the historical ESP cohort (P = 0.144). No PNF occurred in the NMP group, compared with four cases in the historical controls (P versus 8 per cent respectively; P = 0.347). The proportion of patients with DGF was 4 of 11 (36 per cent) in the NMP group versus 53 per cent in the historical controls (P = 0.320). Median duration of DGF was 15.5 (i.q.r. 8.3–98.5) days in the NMP group and 14.5 (5.5–26.8) days in the controls (P = 0.602). One of the four patients with DGF in the NMP group was pre-emptive and developed DGF as a result of atrial fibrillation with haemodynamic instability, requiring cardiopulmonary resuscitation followed by admission to the ICU. Fig. 2 shows similar creatinine and eGFR trajectories in the first week after transplantation and at 30 days in NMP and historical control groups. Groups did not differ in patient or (death-censored) graft survival, incidence of BPAR, or proportion of patients with an eGFR above 30 ml/min after 3, 6 and 12 months (Table 4). No differences in eGFR were observed between the groups at 3 months (P = 0.510), 6 months (P = 0.482) and 1 year (P = 0.908) (Fig. 3).

**Normothermic machine perfusion versus contralateral kidneys**

Eight kidneys were eligible for comparison with the contralateral kidney, as one kidney was not transplanted (unknown reasons) and the other two contralateral kidneys both underwent NMP in this study. Second warm ischaemia time was significantly shorter in the NMP group (median 19 (i.q.r. 17–22) min versus 40 (37–
necrosis without rejection. The 1-year death-censored graft survival rate was 100 per cent in the NMP group and 80 per cent in the contralateral kidney group ($P = 0.206$, log rank test). The 1-year uncensored graft survival rate was 86 per cent in the NMP group and 80 per cent in the contralateral kidney group ($P = 0.637$). The 1-year patient survival rate was 86 per cent in the NMP group and 75 per cent in the contralateral kidney group ($P = 0.731$). Rejection occurred in two kidney pairs in both kidneys and in one pair only in the NMP kidney. At 3 months, creatinine levels were determined for all eight kidney pairs and found to be similar between two kidney pairs (Fig. 4). For four kidney pairs the creatinine concentration was lower in the NMP group, and for two kidney pairs creatinine levels were higher in the NMP group. The NMP kidney of donor 8 had a prolonged DGF based on acute tubular necrosis with discontinuation of haemodialysis after 3 months. Unfortunately, creatinine levels remained above 300 $\mu$mol/l. The NMP kidney of donor 5 experienced vascular rejection at the 3-month creatinine measurement; this recovered fully, with a creatinine concentration at 1 year of 120 $\mu$mol/l.

Paired analysis showed a median 3-month creatinine level of 166.5 (i.q.r. 139.8–203.5) $\mu$mol/l in the NMP group and 176 (125.3–273.8) $\mu$mol/l in the contralateral kidney group ($P = 0.779$).

### Table 4 Comparison of clinical outcomes in normothermic machine perfusion group and historical controls

|                                      | NMP group ($n = 11$) | Historical control group ($n = 53$) | $P^x$ |
|--------------------------------------|----------------------|-------------------------------------|-------|
| Immediate function                   | 7 (64)               | 21 (40)                             | 0.144 |
| PNF                                 | 0 (0)                | 4 (8)                               | 0.347 |
| DGF                                 | 4 (36)               | 28 (53)                             | 0.320 |
| Duration in DGF (days)              | 15.5 (8.3–98.5)      | 14.5 (5.5–26.8)                     | 0.602 |
| eGFR $>30$ ml/min                    |                      |                                     |       |
| 3 months                             | 7 (64)               | 26 (49)                             | 0.379 |
| 6 months                             | 6 (55)               | 29 (55)                             | 0.992 |
| 1 year                               | 6 (55)               | 31 (58)                             | 0.809 |
| BPAR                                 | 4 (36)               | 14 (26)                             | 0.504 |
| 1-year graft survival (%)            | 81                   | 85                                  | 0.575 |
| 1-year graft survival, DC (%)        | 91                   | 91                                  | 0.537 |
| 1-year patient survival (%)          | 91                   | 91                                  | 0.560 |

Values in parentheses are percentages unless indicated otherwise; $^*values are median (i.q.r.). NMP, normothermic machine perfusion; PNF, primary non-function; DGF, delayed graft function; eGFR, estimated glomerular filtration rate; BPAR, biopsy-proven acute rejection; DC, death-censored. $^x\chi^2$ or Fisher’s exact test, except $^\daggerMann–Whitney U$ test and $^\ddagger$log rank test.

### Discussion

This pilot study described experience with 2 h of NMP and supports the feasibility and safety of implementation of NMP in this...
frail patient group. No adverse events were noted during or after NMP. Moreover, analyses for graft outcome showed overall comparable kidney function in NMP and standard preserved kidneys, indicating the safety of NMP in this ESP group. An interesting finding is the observed difference in immediate function between NMP kidneys and the historical controls. Although this did not reach statistical significance owing to the small sample size, the magnitude of the difference suggests that the technique of NMP may be clinically relevant.

The results concerning the impact of NMP on the incidence of DGF are comparable with the first clinical study of 18 ECD–DBD donor kidneys by the Cambridge group\textsuperscript{11}, who found a statistically significant difference in DGF with an incidence of 36 per cent in the control group and 6 per cent in the NMP group (\(P = 0.014\)). The impact of NMP on DGF is probably mediated by interference with ischaemia–reperfusion injury (IRI). ESP kidneys are more vulnerable to IRI, due to increased donor age and comorbidity of the donor. Even though no active therapy was given during NMP, a recent study\textsuperscript{17} showed that kidneys after NMP followed by simulated transplantation had upregulated pathways, promoting cell proliferation, compared with kidneys that were kept on SCS. This shows that NMP itself may already have a positive effect on the donor kidney, and may explain the difference in DGF incidence.

One of the strengths of this study is the use of a paired analysis with the contralateral kidney as a control group. The comparisons made with the historical cohort are confounded; this was addressed by also analysing the outcomes for the contralateral kidney of the same donor. Another strength is that cannulation and attaching the kidney to the Kidney Assist was carried out by one surgeon, which reduces variability in this technique that may have affected quality of NMP. A limitation may be that the donor kidneys were stored for a short period on SCS after NMP for logistical reasons. This could have counteracted the benefit of NMP. However, this risk is deemed small as previous studies\textsuperscript{18–21} have shown that NMP may be also beneficial if carried out at an earlier stage in the total cold ischaemia time.

Unfortunately, one protocol violation took place where one of the kidneys was from a donor nearly 64 years of age instead of 65 years or older. This may have affected graft outcomes, as the cut-off age for the ESP is 65 years. However, as the primary outcome was safety and feasibility, it was decided to include this patient in the analyses. Finally, a recent study\textsuperscript{22} showed that DGF appears not to correlate well with long-term graft survival outcomes in DCD kidney transplantation. However, a lower incidence of DGF may decrease healthcare costs by decreasing the need for dialysis treatment following transplant and shortening the length of hospital stay\textsuperscript{22,23}. A longer follow-up is needed to study the impact of NMP on long-term graft outcomes.

The present study protocol differed slightly from that presented by the Cambridge group\textsuperscript{11}. First, the present study performed 2 h of NMP, in contrast to the Cambridge group who performed 1 h. A few adjustments could be considered to optimize the NMP procedure in the future. First, assuming that NMP of longer duration is beneficial, the addition of albumin may be recommended to increase the osmotic pressure, preventing oedema\textsuperscript{26,27}. Second, in the present protocol urine output was recirculated as a previous study\textsuperscript{16} showed this to be superior in maintaining homeostasis, rather than replacing urine production with Ringer’s lactate. However, if longer perfusion times are to be realized, control of waste products may be necessary and the addition of a dialysis membrane in combination with a haemoadsorption filter may be beneficial to clear waste products and proinflammatory cytokines\textsuperscript{28}. Lastly, the risk of allosensitization can be addressed by using an acellular perfusion solution containing a haemoglobin-based oxygen carrier, which has been shown to be at least as effective as a blood-based perfusate for liver NMP\textsuperscript{29}.
The findings of this pilot study support the performance of a larger study to explore further the potential efficacy of NMP to improve graft outcome. As a next step, the focus should be on exploring the safety of prolonged NMP and the possibility of administering therapy that specifically targets IRI. Currently, an RCT is being carried out in the UK, comparing NMP with SCS. This trial will help to identify biomarkers and perfusion cut-off values to define required length of perfusion. NMP not only has the potential to improve outcome in kidneys accepted according to current standards, but might also reduce discard rates, as Hosgood et al.9 showed recently in a small study of 10 kidneys declined for transplantation, where NMP led to 50 per cent of kidneys eventually being transplanted.

Funding
Coolsingel Foundation (‘Stichting Coolsingel’, project number 557)
This study was funded by the Coolsingel Foundation (‘Stichting Coolsingel’). The funder was not involved in the research design, data collection, analysis, or manuscript preparation.

Acknowledgements
The authors express their gratitude to the Coolsingel Foundation (Stichting Coolsingel) for providing the funding to undertake this study. They also thank the Dutch Transplantation Society and Eurotransplant for providing the data from the contralateral kidneys. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available owing to privacy or ethical restrictions. This study was not preregistered.

Disclosure. The authors declare no conflict of interest.

References
1. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D et al. Systematic review: kidney transplantation compared with dialysis in clinically relevant outcomes. Am J Transplant 2011;11: 2093–2109
2. Batabyal P, Chapman JR, Wong G, Craig JC, Tong A. Clinical practice guidelines on wait-listing for kidney transplantation: consistent and equitable? Transplantation 2012;94:703–713
3. Port FK, Bragg-Gresham JL, Metzger RA, Dykstra DM, Gillespie BW, Young EW et al. Donor characteristics associated with reduced graft survival: an approach to expanding the pool of kidney donors. Transplantation 2002;74:1281–1286
4. Cohen B, Smits JM, Haase B, Persijn G, Vannrenterghem Y, Frei U. Expanding the donor pool to increase renal transplantation. Nephrol Dial Transplant 2005;20:34–41
5. Frei U, Noedelke J, Machold-Fabrizii V, Arbogast H, Margreiter R, Frickel E et al. Prospective age-matching in elderly kidney transplant recipients—a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant 2008;8:50–57
6. Peters-Sengers H, Berger SP, Heemskerk MB, Al Arashi D, Homan van der Heide JI, Hemke AC et al. Stretching the limits of renal transplantation in elderly recipients of grafts from elderly deceased donors. J Am Soc Nephrol 2017;28:621–631
7. Moers C, Smits JM, Maathuis MH, Treckmann J, van Gelder F, Napieralski BP et al. Machine perfusion or cold storage in deceased-donor kidney transplantation. N Engl J Med 2009;360:7–19
8. Gallinat A, Moers C, Treckmann J, Smits JM, Leuvenink HG, Lefering R et al. Machine perfusion versus cold storage for the preservation of kidneys from donors ≥65 years allocated in the Eurotransplant Senior Programme. Nephrol Dial Transplant 2012; 27:4458–4463
9. Hosgood SA, Thompson E, Moore T, Wilson CH, Nicholson ML. Normothermic machine perfusion for the assessment and transplantation of declined human kidneys from donation after circulatory death donors. Br J Surg 2018;105:388–394
10. Chandak P, Phillips BL, Uwechue R, Thompson E, Bates L, Ibrahim I et al. Dissemination of a novel organ perfusion technique: ex vivo normothermic perfusion of deceased donor kidneys. Artif Organs 2019;43:E308–E319
11. Nicholson ML, Hosgood SA. Renal transplantation after ex vivo normothermic perfusion: the first clinical study. Am J Transplant 2013;13:1246–1252
12. Gregorini M, Corradetti V, Pattonieri EF, Roca C, Milanesi S, Peloso A et al. Perfusion of isolated rat kidney with mesenchymal stromal cells/extracellular vesicles prevents ischaemic injury. J Cell Mol Med 2017;21:3381–3393
13. Sierra-Parraga JM, Eijken M, Hunter J, Moers C, Leuvenink H, Moller B et al. Mesenchymal stromal cells as anti-inflammatory and regenerative mediators for donor kidneys during normothermic machine perfusion. Stem Cells Dev 2017;26:1162–1170
14. Hosgood SA, Nicholson ML. First in man renal transplantation after ex vivo normothermic perfusion. Transplantation 2011;92:735–738
15. Minor T, von Horn C, Gallinat A, Kaths M, Kribben A, Treckmann J et al. First-in-man controlled rewarming and normothermic perfusion with cell-free solution of a kidney prior to transplantation. Am J Transplant 2020;20:1192–1195
16. Weissenbacher A, Lo Faro L, Boutriak O, Soares MF, Roberts IS, Hunter JP et al. Twenty-four-hour normothermic perfusion of discarded human kidneys with urine recirculation. Am J Transplant 2019;19:178–192
17. Hameed AM, Lu DB, Patrick E, Xu B, Hu M, Chew YY et al. Brief normothermic machine perfusion rejuvenates discarded human kidneys. Transplant Direct 2019;5:e502
18. Hosgood SA, Nicholson ML. The first clinical case of intermediate ex vivo normothermic perfusion in renal transplantation. Am J Transplant 2014;14:1690–1692
19. Maessen JG, van der Vusse GJ, Vork M, Kootstra G. The beneficial effect of intermediate normothermic perfusion during cold storage of ischemically injured kidneys. A study of renal nucleotide homeostasis during hypothermia in the dog. Transplantation 1989;47:409–414
20. Rijkmans BG, Buurman WA, Kootstra G. Six-day canine kidney preservation. Hypothermic perfusion combined with isolated blood perfusion. Transplantation 1984;37:130–134
21. van der Wijk J, Slooff MJ, Rijkmans BG, Kootstra G. Successful 96- and 144-hour experimental kidney preservation: a combination of standard machine preservation and newly developed normothermic ex vivo perfusion. Cryobiology 1980;17:473–477
22. de Kok MJ, McGuinness D, Shiels PG, de Vries DK, Nolthenius JBT, Wijermars LG et al. The neglectable impact of delayed graft function on long-term graft survival in kidneys donated after circulatory death associates with superior organ resilience. Ann Surg 2019;270:877–883
23. Incerti D, Summers N, Ton TGN, Boscoe A, Chandraker A, Stevens W. The lifetime health burden of delayed graft function
in kidney transplant recipients in the United States. MDM Policy Pract 2018;3:2381468318781811

24. Kath JM, Echeverri J, Linares I, Cen JY, Ganesh S, Hamar M et al. Normothermic ex vivo kidney perfusion following static cold storage-brief, intermediate, or prolonged perfusion for optimal renal graft reconditioning? Am J Transplant 2017;17:2580–2590

25. Oriol I, Sabe N, Tebe C, Veroux M, Boin I, Carratala J. Clinical impact of culture-positive preservation fluid on solid organ transplantation: a systematic review and meta-analysis. Transplant Rev (Orlando) 2018;32:85–91

26. Schurek HJ, Alt JM. Effect of albumin on the function of perfused rat kidney. Am J Physiol 1981;240:F569–F576

27. Urcuyo D, Blum MF, Liu Q, Nassar A, Buccini LD, Diago Uso T et al. Development of a prolonged warm ex vivo perfusion model for kidneys donated after cardiac death. Int J Artif Organs 2017;40:265–271

28. Hosgood SA, Moore T, Kleverlaan T, Adams T, Nicholson ML. Haemoadsorption reduces the inflammatory response and improves blood flow during ex vivo renal perfusion in an experimental model. J Transl Med 2017;15:216

29. Matton APM, Burlage LC, van Rijn R, de Vries Y, Karangwa SA, Nijsten MW et al. Normothermic machine perfusion of donor livers without the need for human blood products. Liver Transpl 2018;24:528–538